Basic | |
---|---|
Market Cap | $0 |
Price | $0.19 |
52 Week Range | 0.141-1.58 |
Beta | 0.56 |
Margins | |
Gross Profit Margin | -51.35% |
Operating Profit Margin | -2389.19% |
Net Profit Margin | -3406.91% |
Valuation (TTM) | |
P/E Ratio | -0.05 |
Price to Sales Ratio | 0.00 |
Price to Book Ratio | 0.11 |
PEG Ratio | -0.00 |
Biotechnology
Healthcare
4
2021-04-01T00:00:00.000Z
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.
201 479 1357
2 Executive Campus, Cherry Hill, NJ, 08002, US
0001349929